Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives $17.25 Consensus PT from Brokerages

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given an average recommendation of “Hold” by the six brokerages that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.25.

Several brokerages have issued reports on AUPH. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, January 21st. Leerink Partners lowered shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $15.00 to $16.00 in a research report on Wednesday, December 3rd. Bloom Burton downgraded shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $10.00 to $21.00 in a research note on Friday, November 7th.

Aurinia Pharmaceuticals Trading Down 1.0%

Shares of AUPH stock opened at $14.57 on Wednesday. The company has a current ratio of 5.76, a quick ratio of 5.17 and a debt-to-equity ratio of 0.15. Aurinia Pharmaceuticals has a 12-month low of $6.55 and a 12-month high of $16.54. The stock has a market capitalization of $1.92 billion, a P/E ratio of 26.02 and a beta of 1.46. The firm’s 50 day moving average is $15.56 and its 200 day moving average is $13.19.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.07. The business had revenue of $73.47 million during the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. Research analysts expect that Aurinia Pharmaceuticals will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Prakash Investment Advisors LLC bought a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $211,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Aurinia Pharmaceuticals by 10.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,681 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 4,587 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 1,318 shares in the last quarter. CWM LLC boosted its holdings in Aurinia Pharmaceuticals by 15.5% in the 4th quarter. CWM LLC now owns 16,543 shares of the biotechnology company’s stock worth $264,000 after buying an additional 2,225 shares during the period. Finally, PFG Investments LLC boosted its holdings in Aurinia Pharmaceuticals by 39.4% in the 4th quarter. PFG Investments LLC now owns 34,440 shares of the biotechnology company’s stock worth $549,000 after buying an additional 9,740 shares during the period. 36.83% of the stock is currently owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.